Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Ryan K, Anderson M, Gyurova I, Ambroggio L, Moyo S, Sebunya T, Makhema J, Marlink R, Essex M, Musonda R, Gaseitsiwe S, Blackard JT. High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana. Open Forum Infect Dis 2017;4:ofx195. [PMID: 29062862 PMCID: PMC5641381 DOI: 10.1093/ofid/ofx195] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Accepted: 09/12/2017] [Indexed: 12/16/2022] Open

For:	Ryan K, Anderson M, Gyurova I, Ambroggio L, Moyo S, Sebunya T, Makhema J, Marlink R, Essex M, Musonda R, Gaseitsiwe S, Blackard JT. High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana. Open Forum Infect Dis 2017;4:ofx195. [PMID: 29062862 PMCID: PMC5641381 DOI: 10.1093/ofid/ofx195] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Accepted: 09/12/2017] [Indexed: 12/16/2022] Open

Number

Cited by Other Article(s)

Phinius BB, Choga WT, Anderson M, Mokomane M, Gobe I, Ratsoma T, Phakedi B, Mpebe G, Bhebhe L, Gaolathe T, Mosepele M, Makhema J, Shapiro R, Lockman S, Musonda R, Moyo S, Gaseitsiwe S. Molecular Characterization of Hepatitis B Virus in People Living with HIV in Rural and Peri-Urban Communities in Botswana. Biomedicines 2024;12:1561. [PMID: 39062134 PMCID: PMC11275055 DOI: 10.3390/biomedicines12071561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2024] [Revised: 07/10/2024] [Accepted: 07/12/2024] [Indexed: 07/28/2024] Open

Affiliation(s)

Bonolo B. Phinius Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag UB0022, Botswana; (M.M.); (I.G.)
Wonderful T. Choga Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag UB0022, Botswana; (M.M.); (I.G.)
Motswedi Anderson Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) Africa Health Research Institute (AHRI), Private Bag X7, Congella, Durban 4013, South Africa The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
Margaret Mokomane School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag UB0022, Botswana; (M.M.); (I.G.)
Irene Gobe School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag UB0022, Botswana; (M.M.); (I.G.)
Tsholofelo Ratsoma Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.)
Basetsana Phakedi Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.)
Gorata Mpebe Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.)
Lynnette Bhebhe Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.)
Tendani Gaolathe Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) Faculty of Medicine, University of Botswana, Gaborone Private Bag UB0022, Botswana
Mosepele Mosepele Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) Faculty of Medicine, University of Botswana, Gaborone Private Bag UB0022, Botswana
Joseph Makhema Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
Roger Shapiro Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
Shahin Lockman Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
Rosemary Musonda Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
Sikhulile Moyo Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone Private Bag UB0022, Botswana; (M.M.); (I.G.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Private Bag X1, Matieland, Cape Town 7602, South Africa School of Health Systems and Public Health, University of Pretoria, Private Bag X20, Pretoria 0028, South Africa
Simani Gaseitsiwe Botswana Harvard Health Partnership, Gaborone Private Bag BO320, Botswana; (B.B.P.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA

Collapse

Bazie MM, Sanou M, Djigma FW, Compaore TR, Obiri-Yeboah D, Kabamba B, Nagalo BM, Simpore J, Ouédraogo R. Genetic diversity and occult hepatitis B infection in Africa: A comprehensive review. World J Hepatol 2024;16:843-859. [PMID: 38818293 PMCID: PMC11135261 DOI: 10.4254/wjh.v16.i5.843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 02/06/2024] [Accepted: 04/15/2024] [Indexed: 05/22/2024] Open

Anderson M, Phinius BB, Phakedi BK, Mudanga M, Bhebhe LN, Tlhabano GN, Motshosi P, Ratsoma T, Baruti K, Mpebe G, Choga WT, Marlink R, Glebe D, Blackard JT, Moyo S, Kramvis A, Gaseitsiwe S. Persistence and risk factors of occult hepatitis B virus infections among antiretroviral therapy-naïve people living with HIV in Botswana. Front Microbiol 2024;15:1342862. [PMID: 38784816 PMCID: PMC11112038 DOI: 10.3389/fmicb.2024.1342862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Accepted: 04/22/2024] [Indexed: 05/25/2024] Open

Affiliation(s)

Motswedi Anderson Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana
Bonolo B. Phinius Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana
Basetsana K. Phakedi Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana
Mbatshi Mudanga Botswana – University of Maryland School of Medicine Health Initiative, Gaborone, Botswana
Lynnette N. Bhebhe Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana
Girlie N. Tlhabano Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana
Patience Motshosi Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana
Tsholofelo Ratsoma Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana
Kabo Baruti Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana
Gorata Mpebe Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana
Wonderful T. Choga Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana
Richard Marlink Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, United States
Dieter Glebe Institute of Medical Virology, National Reference Centre for Hepatitis B Viruses and Hepatitis D Viruses, Justus Liebig University of Giessen, Giessen, Germany
Jason T. Blackard Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, United States
Sikhulile Moyo Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States Division of Medical Virology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa
Anna Kramvis Hepatitis Virus Diversity Research Unit, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa
Simani Gaseitsiwe Research Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States

Collapse

Phinius BB, Anderson M, Gobe I, Mokomane M, Choga WT, Phakedi B, Ratsoma T, Mpebe G, Makhema J, Shapiro R, Lockman S, Musonda R, Moyo S, Gaseitsiwe S. High Prevalence of Hepatitis B Virus Drug Resistance Mutations to Lamivudine among People with HIV/HBV Coinfection in Rural and Peri-Urban Communities in Botswana. Viruses 2024;16:592. [PMID: 38675933 PMCID: PMC11054684 DOI: 10.3390/v16040592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Revised: 04/07/2024] [Accepted: 04/09/2024] [Indexed: 04/28/2024] Open

Affiliation(s)

Bonolo B. Phinius Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (I.G.); (M.M.)
Motswedi Anderson Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.)
Irene Gobe School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (I.G.); (M.M.)
Margaret Mokomane School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (I.G.); (M.M.)
Wonderful T. Choga Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (I.G.); (M.M.)
Basetsana Phakedi Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.)
Tsholofelo Ratsoma Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.)
Gorata Mpebe Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.)
Joseph Makhema Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
Roger Shapiro Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
Shahin Lockman Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
Rosemary Musonda Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.)
Sikhulile Moyo Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (I.G.); (M.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland 7602, South Africa School of Health Systems and Public Health, University of Pretoria, Private Bag X20, Pretoria 0028, South Africa
Simani Gaseitsiwe Botswana Harvard Health Partnership, Private Bag BO320, Gaborone, Botswana; (B.B.P.); (M.A.); (G.M.); (J.M.); (R.S.); (S.L.); (R.M.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA

Collapse

MPEBE GG, PHINIUS BB, MUTENGA S, BARUTI K, BHEBHE L, CHOGA WT, JONGMAN M, PRETORIUS-HOLME M, GAOLATHE T, MMALANE M, SHAPIRO R, MAKHEMA J, LOCKMAN S, MOYO S, ANDERSON M, GASEITSIWE S. Hepatitis B surface antigen loss in individuals with chronic hepatitis B virus and HIV-1 infections in Botswana. AIDS 2024;38:153-159. [PMID: 37861688 PMCID: PMC11249093 DOI: 10.1097/qad.0000000000003753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2023]

Affiliation(s)

Gorata G.A MPEBE Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana
Bonolo B. PHINIUS Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana
Sharon MUTENGA Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Midlands State University, Gweru, Zimbabwe
Kabo BARUTI Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana
Lynnette BHEBHE Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Wonderful T. CHOGA Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana
Mosimanegape JONGMAN Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana
Molly PRETORIUS-HOLME Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
Tendani GAOLATHE Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Mompati MMALANE Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
Roger SHAPIRO Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
Joseph MAKHEMA Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
Shahin LOCKMAN Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
Sikhulile MOYO Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA School of Health Systems and Public Health, University of Pretoria, Gauteng, South Africa
Motswedi ANDERSON Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Simani GASEITSIWE Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

Collapse

Millar J, Cromhout GZL, Mchunu N, Bengu N, Ndung’u T, Goulder PJ, Matthews PC, McNaughton AL. Hepatitis B Virus Prevalence and Mother-to-Child Transmission Risk in an HIV Early Intervention Cohort in KwaZulu-Natal, South Africa. Open Forum Infect Dis 2023;10:ofad366. [PMID: 37547854 PMCID: PMC10400149 DOI: 10.1093/ofid/ofad366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Accepted: 07/13/2023] [Indexed: 08/08/2023] Open

Phinius BB, Anderson M, Mokomane M, Gobe I, Choga WT, Ratsoma T, Phakedi B, Mpebe G, Ditshwanelo D, Musonda R, Makhema J, Moyo S, Gaseitsiwe S. Atypical Hepatitis B Virus Serology Profile-Hepatitis B Surface Antigen-Positive/Hepatitis B Core Antibody-Negative-In Hepatitis B Virus/HIV Coinfected Individuals in Botswana. Viruses 2023;15:1544. [PMID: 37515230 PMCID: PMC10383918 DOI: 10.3390/v15071544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 07/10/2023] [Accepted: 07/11/2023] [Indexed: 07/30/2023] Open

Affiliation(s)

Bonolo B. Phinius Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (M.M.); (I.G.)
Motswedi Anderson Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.)
Margaret Mokomane School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (M.M.); (I.G.)
Irene Gobe School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (M.M.); (I.G.)
Wonderful T. Choga Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (M.M.); (I.G.)
Tsholofelo Ratsoma Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.)
Basetsana Phakedi Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.)
Gorata Mpebe Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.)
Doreen Ditshwanelo Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.)
Rosemary Musonda Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.)
Joseph Makhema Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
Sikhulile Moyo Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.) School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Private Bag UB 0022, Gaborone, Botswana; (M.M.); (I.G.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA School of Health Systems and Public Health, University of Pretoria, Private Bag X20, Hatfield, Pretoria 0028, South Africa
Simani Gaseitsiwe Botswana Harvard AIDS Institute Partnership, Private Bag BO 320, Gaborone, Botswana; (B.B.P.); (M.A.); (W.T.C.); (T.R.); (B.P.); (G.M.); (D.D.); (R.M.); (J.M.); (S.M.) Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA

Collapse

Phinius BB, Anderson M, Gobe I, Mokomane M, Choga WT, Mutenga SR, Mpebe G, Pretorius-Holme M, Musonda R, Gaolathe T, Mmalane M, Shapiro R, Makhema J, Lockman S, Novitsky V, Essex M, Moyo S, Gaseitsiwe S. High Prevalence of Hepatitis B Virus Infection Among People With HIV in Rural and Periurban Communities in Botswana. Open Forum Infect Dis 2023;10:ofac707. [PMID: 36686633 PMCID: PMC9850276 DOI: 10.1093/ofid/ofac707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Accepted: 01/05/2023] [Indexed: 01/09/2023] Open

Affiliation(s)

Bonolo B Phinius Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana School of Allied Health Professions, Faculty of Health Sciences, University of Botswana,Gaborone, Botswana
Motswedi Anderson Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana School of Allied Health Professions, Faculty of Health Sciences, University of Botswana,Gaborone, Botswana
Irene Gobe School of Allied Health Professions, Faculty of Health Sciences, University of Botswana,Gaborone, Botswana
Margaret Mokomane School of Allied Health Professions, Faculty of Health Sciences, University of Botswana,Gaborone, Botswana
Wonderful T Choga Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Sharon R Mutenga Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Applied Biological Sciences and Biotechnology, Faculty of Science and Technology, Midlands State University, Gweru, Zimbabwe
Gorata Mpebe Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Biological Sciences, Faculty of Sciences, University of Botswana,Gaborone, Botswana
Molly Pretorius-Holme Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Rosemary Musonda Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Tendani Gaolathe Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
Mompati Mmalane Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Roger Shapiro Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Joseph Makhema Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Shahin Lockman Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Vlad Novitsky Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Max Essex Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Sikhulile Moyo Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Simani Gaseitsiwe Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA

Collapse

Ondigui JLN, Kenmoe S, Kengne-Ndé C, Ebogo-Belobo JT, Takuissu GR, Kenfack-Momo R, Mbaga DS, Tchatchouang S, Kenfack-Zanguim J, Fogang RL, Menkem EZ, Kame-Ngasse GI, Magoudjou-Pekam JN, Bowo-Ngandji A, Goumkwa NM, Esemu SN, Ndip L, Essama SHR, Torimiro J. Epidemiology of occult hepatitis B and C in Africa: A systematic review and meta-analysis. J Infect Public Health 2022;15:1436-1445. [PMID: 36395668 PMCID: PMC7613883 DOI: 10.1016/j.jiph.2022.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Revised: 11/04/2022] [Accepted: 11/08/2022] [Indexed: 11/13/2022] Open

Abstract

BACKGROUND

Occult hepatitis B (OBI) and C (OCI) infections lead to hepatic crises including cases of liver cirrhosis and even hepatocellular carcinoma (HCC). OBI and OCI also pose a significant problem of their transmissibility. This study aimed to assess the overall prevalence of OBI and OCI in the African continent, a region highly endemic for classical hepatitis B and C viruses.

METHODS

For this systematic review and meta-analysis, we searched: PubMed, Web of Science, African Journal Online and African Index Medicus for published studies on the prevalence of OBI and OCI in Africa. Study selection and data extraction were performed by at least two independent investigators. Heterogeneity (I²) was assessed using the χ² test on the Cochran Q statistic and H parameters. Sources of heterogeneity were explored by subgroup analyses. This study was registered in PROSPERO, with reference number CRD42021252772.

RESULTS

We obtained 157 prevalence data for this meta-analysis, from 134 studies for OBI prevalence; 23 studies on OCI prevalence, and a single study on the OBI case fatality rate. The overall estimate for the prevalence of OBI was 14.8% [95% CI = 12.2-17.7] among 18579 participants. The prevalence of seronegative OBI and seropositive OBI was 7.4% [95% CI = 3.8-11.8] and 20.0% [95% CI = 15.3-25.1] respectively. The overall estimate for the prevalence of OCI was 10.7% [95% CI = 6.6-15.4] among 2865 participants. The pooled prevalence of seronegative OCI was estimated at 10.7% [95%CI = 4.8-18.3] and that of seropositive OCI at 14.4% [95%CI = 5.2-22.1]. In Sub-group analysis, patients with malignancies, chronic hepatitis C, and hemodialysis had a higher OCI prevalence. While those with malignancies, liver disorders, and HIV positive registered highest OBI prevalence.

CONCLUSION

This review shows a high prevalence of OBI and OCI in Africa, with variable prevalence between countries and population groups.

Collapse

Affiliation(s)

Juliette Laure Ndzie Ondigui Department of Microbiology, The University of Yaounde I, Yaounde, Cameroon; Molecular Biology Laboratory, Chantal Biya International Reference Centre for AIDS Research (CIRCB), Yaounde, Cameroon
Sebastien Kenmoe Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon.
Cyprien Kengne-Ndé Epidemiological Surveillance, Evaluation and Research Unit, National AIDS Control Committee, Douala, Cameroon
Jean Thierry Ebogo-Belobo Medical Research Centre, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon
Guy Roussel Takuissu Centre for Food, Food Security and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon
Raoul Kenfack-Momo Department of Biochemistry, The University of Yaounde I, Yaounde, Cameroon
Donatien Serge Mbaga Department of Microbiology, The University of Yaounde I, Yaounde, Cameroon
Serges Tchatchouang Scientific Direction, Centre Pasteur of Cameroon, Yaounde, Cameroon
Josiane Kenfack-Zanguim Department of Biochemistry, The University of Yaounde I, Yaounde, Cameroon
Robertine Lontuo Fogang Department of Animal Biology, University of Dschang, Dschang, Cameroon
Elisabeth Zeuko'o Menkem Department of Biomedical Sciences, University of Buea, Buea, Cameroon
Ginette Irma Kame-Ngasse Medical Research Centre, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon
Jeannette Nina Magoudjou-Pekam Department of Biochemistry, The University of Yaounde I, Yaounde, Cameroon
Arnol Bowo-Ngandji Department of Microbiology, The University of Yaounde I, Yaounde, Cameroon
Nadège Mafopa Goumkwa Molecular Biology Laboratory, Chantal Biya International Reference Centre for AIDS Research (CIRCB), Yaounde, Cameroon
Seraphine Nkie Esemu Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon
Lucy Ndip Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon
Sara Honorine Riwom Essama Department of Microbiology, The University of Yaounde I, Yaounde, Cameroon
Judith Torimiro Molecular Biology Laboratory, Chantal Biya International Reference Centre for AIDS Research (CIRCB), Yaounde, Cameroon

Collapse

Lalana Garcés M, Ortiz Pastor O, Solé Enrech G, Guerra-Ruiz AR, Casals Mercadal G, Almería Lafuente A, Ballesteros Vizoso MA, Medina PG, Salgüero Fernández S, Zamora Trillo A, Aured de la Serna I, Hurtado JC, Pérez-Del-Pulgar S, Forns X, Morales Ruiz M. Control of occult hepatitis B virus infection. ADVANCES IN LABORATORY MEDICINE / AVANCES EN MEDICINA DE LABORATORIO 2022. [DOI: 10.1515/almed-2022-0065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]

Affiliation(s)

Marta Lalana Garcés Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Análisis Clínicos, Hospital de Barbastro , Huesca , Spain
Oihana Ortiz Pastor Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Bioquímica Clínica, Hospital Universitario Miguel Servet , Zaragoza , Spain
Gemma Solé Enrech Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servei de laboratori, UDIAT-CD, Corporació Sanitaria Parc Taulí , Sabadell , Spain
Armando R. Guerra-Ruiz Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Análisis Clínicos, Hospital Universitario Marqués de Valdecilla , Santander , Spain
Gregori Casals Mercadal Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Bioquímica y Genética Molecular, CDB, Hospital Clínic de Barcelona, IDIBAPS, CIBEREHD , Barcelona , Spain
Alejandro Almería Lafuente Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Bioquímica Clínica, Hospital Royo Villanova , Zaragoza , Spain
María Antonieta Ballesteros Vizoso Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Análisis Clínicos, Hospital Universitario Son Espases , Palma de Mallorca , Spain
Pablo Gabriel Medina Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Bioquímica Clínica, Hospital Universitari Vall d’Hebron , Barcelona , Spain
Sergio Salgüero Fernández Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Análisis Clínicos, Hospital Universitario Fundación Alcorcón , Madrid , Spain
Angielys Zamora Trillo Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Bioquímica Clínica, Hospital General Universitario Gregorio Marañón , Madrid , Spain
Isabel Aured de la Serna Servicio de Digestivo, Hospital de Barbastro , Huesca , Spain
Juan Carlos Hurtado Servicio de Microbiología, CDB, Hospital Clínic de Barcelona, Universitat de Barcelona , Barcelona , Spain Instituto de Salud Global de Barcelona (ISGlobal) , Barcelona , Spain
Sofía Pérez-Del-Pulgar Servicio de Hepatología, Hospital Clínic de Barcelona, IDIBAPS, CIBEREHD , Barcelona , Spain
Xavier Forns Servicio de Hepatología, Hospital Clínic de Barcelona, IDIBAPS, CIBEREHD , Barcelona , Spain
Manuel Morales Ruiz Comisión de Valoración Bioquímica de la Enfermedad Hepática, Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , Spain Servicio de Bioquímica y Genética Molecular, CDB, Hospital Clínic de Barcelona, IDIBAPS, CIBEREHD , Barcelona , Spain Departamento de Biomedicina de la Facultad de Medicina y Ciencias de la Salud-Universidad de Barcelona , Barcelona , Spain

Collapse

Lalana Garcés M, Pastor OO, Solé Enrech G, Guerra-Ruiz AR, Mercadal GC, Almería Lafuente A, Ballesteros Vizoso MA, Medina PG, Salgüero Fernández S, Zamora Trillo A, Aured de la Serna I, Hurtado JC, Pérez-Del-Pulgar S, Forns X, Morales Ruiz M. Revisión de la infección oculta por el virus de la hepatitis B. ADVANCES IN LABORATORY MEDICINE / AVANCES EN MEDICINA DE LABORATORIO 2022. [DOI: 10.1515/almed-2021-0084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]

Affiliation(s)

Marta Lalana Garcés Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Análisis Clínicos , Hospital de Barbastro , Huesca , España
Oihana Ortiz Pastor Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Bioquímica Clínica , Hospital Universitario Miguel Servet , Zaragoza , España
Gemma Solé Enrech Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servei de laboratori , UDIAT-CD. Corporació Sanitaria Parc Taulí , Sabadell , España
Armando Raul Guerra-Ruiz Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Análisis Clínicos , Hospital Universitario Marqués de Valdecilla , Santander , España
Gregori Casals Mercadal Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Bioquímica y Genética Molecular, CDB , Hospital Clínic de Barcelona, IDIBAPS, CIBEREHD , Barcelona , España
Alejandro Almería Lafuente Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Bioquímica Clínica , Hospital Royo Villanova , Zaragoza , España
María Antonieta Ballesteros Vizoso Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Análisis Clínicos , Hospital Universitario Son Espases , Palma de Mallorca , España
Pablo Gabriel Medina Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Bioquímica Clínica , Hospital Universitari Vall d’Hebron , Barcelona , España
Sergio Salgüero Fernández Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Análisis Clínicos , Hospital Universitario Fundación Alcorcón , Madrid , España
Angielys Zamora Trillo Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Bioquímica Clínica , Hospital General Universitario Gregorio Marañón , Madrid , España
Isabel Aured de la Serna Servicio de Digestivo , Hospital de Barbastro , Huesca , España
Juan Carlos Hurtado Servicio de Microbiología, CDB, Hospital Clínic de Barcelona , Universitat de Barcelona , Barcelona , España Instituto de Salud Global de Barcelona (ISGlobal) , Barcelona , España
Sofía Pérez-Del-Pulgar Servicio de Hepatología , Hospital Clínic de Barcelona, IDIBAPS, CIBEREHD , Barcelona , España
Xavier Forns Servicio de Hepatología , Hospital Clínic de Barcelona, IDIBAPS, CIBEREHD , Barcelona , España
Manuel Morales Ruiz Comisión de Valoración Bioquímica de la Enfermedad Hepática , Sociedad Española de Medicina de Laboratorio (SEQC-ML) , Barcelona , España Servicio de Bioquímica y Genética Molecular, CDB , Hospital Clínic de Barcelona, IDIBAPS, CIBEREHD , Barcelona , España Departamento de Biomedicina de la Facultad de Medicina y Ciencias de la Salud -Universidad de Barcelona , Barcelona , España

Collapse

Kajogoo VD, Swai SS, Gurung S. Prevalence of occult hepatitis B among HIV-positive individuals in Africa: A systematic review and meta-analysis. SAGE Open Med 2022;10:20503121211072748. [PMID: 35127096 PMCID: PMC8808011 DOI: 10.1177/20503121211072748] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 12/20/2021] [Indexed: 12/16/2022] Open

Abstract The prevalence of hepatitis B virus among HIV-seropositive individuals is believed to be high, and yet the disease remains neglected in many areas of the continent. Little is known about occult hepatitis in HIV individuals. This review assessed occult hepatitis B infection and its prevalence in the different regions of the African continent. It also determines its prevalence in the HIV population which is endemic in the region. Studies were searched from the Cochrane, google scholar, PubMed/Medline, and African Journals online. Authors included cross-sectional studies, case controls, and cohorts, from 2010 to January 2021, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Participants, Interventions, Comparisons, Outcomes, and Study design frameworks to develop the search strategy. All studies had participants who were HIV-positive, covering different regions of the continent. Risk ratio was used to measure effect size, and Stata 14 software was used for analysis. Eleven studies met the eligibility criteria, with 2567 participants. Overall prevalence of occult hepatitis B was 11.2%. Regional prevalence was 26.5% for the south, 11% for the north, 9.1% for the east, and 8.5% for the western region. Approximately 10% of HIV-seropositive individuals were co-infected with occult hepatitis B virus. Regionally, the prevalence was highest in the southern region and lowest in the west. The prevalence of occult HBV infection was compared between the southern region and the other regions. It was higher in the south compared to the east (risk ratio = 0.87, 95% confidence interval (0.83–0.91)). It was also higher in the south compared to the north (risk ratio = 0.82, 95% confidence interval (0.79–0.85)), and it was also higher in the south compared to the west (risk ratio = 0.85, 95% confidence interval (0.82–0.87)). Public health measures and interventions are required to raise awareness, increase prevention, and reduce spread of the disease. More evidence-based studies need to be carried out. Collapse

de Almeida NAA, de Paula VS. Occult Hepatitis B virus (HBV) infection and challenges for hepatitis elimination: A literature review. J Appl Microbiol 2021;132:1616-1635. [PMID: 34724308 DOI: 10.1111/jam.15351] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 09/08/2021] [Accepted: 10/11/2021] [Indexed: 12/15/2022]

Ünlü G, Yıldız Y, Ören MM, Çabalak M, Mete Ö, Kömür S, Yıldırım F, İnan D, Altunışık Toplu S, Akhan S, Karaşahin Ö, Akdemir Kalkan İ, Demir Y, Ayhan M, Karaoğlan İ, Taşova Y, Bayındır Y, Dal T, Çelen MK. Occult hepatitis B infection in Turkish HIV-infected patients: A multicentre, retrospective, cross-sectional study, Schindler study. Int J Clin Pract 2021;75:e14358. [PMID: 33977603 DOI: 10.1111/ijcp.14358] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Accepted: 05/07/2021] [Indexed: 11/30/2022] Open

Affiliation(s)

Gülten Ünlü Infectious Diseases and Clinical Microbiology Clinic, Kocaeli Derince Training and Research Hospital University of Health Science, Kocaeli, Turkey
Yeşim Yıldız Department of Infectious Diseases and Clinical Microbiology, Gazi University Faculty of Medicine, Ankara, Turkey
Meryem Merve Ören Department of Public Health, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey
Mehmet Çabalak Department of Infectious Diseases and Clinical Microbiology, Mustafa Kemal University Medical Faculty, Hatay, Turkey
Özlem Mete Department of Infectious Diseases and Clinical Microbiology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
Süheyla Kömür Department of Infectious Diseases and Clinical Microbiology, Çukurova University Medical Faculty, Adana, Turkey
Figen Yıldırım Clinic of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Turkey
Dilara İnan Department of Infectious Diseases and Clinical Microbiology, Akdeniz University Faculty of Medicine, Antalya, Turkey
Sibel Altunışık Toplu Department of Infectious Diseases and Clinical Microbiology, İnönü University Medical Faculty, Malatya, Turkey
Sıla Akhan Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
Ömer Karaşahin Department of Infectious Diseases and Clinical Microbiology, Erzurum Regional Training and Research Hospital, Erzurum, Turkey
İrem Akdemir Kalkan Department of Infectious Diseases and Clinical Microbiology, Ankara University Faculty of Medicine, Ankara, Turkey
Yakup Demir Department of Infectious Diseases and Clinical Microbiology, Dicle University Faculty of Medicine, Diyarbakır, Turkey
Merve Ayhan Self-Employed Pharmacists, Ela Pharmacy, Batman, Turkey
İlkay Karaoğlan Department of Infectious Diseases and Clinical Microbiology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
Yeşim Taşova Department of Infectious Diseases and Clinical Microbiology, Çukurova University Medical Faculty, Adana, Turkey
Yaşar Bayındır Department of Infectious Diseases and Clinical Microbiology, İnönü University Medical Faculty, Malatya, Turkey
Tuba Dal Medical Microbiology Department, Ankara Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey
Mustafa Kemal Çelen Department of Infectious Diseases and Clinical Microbiology, Dicle University Faculty of Medicine, Diyarbakır, Turkey

Collapse

Souda S, Mwita JC, Cainelli F, Mannathoko NB, Anderson M, Moyo S. Seroprevalence and risk factors of hepatitis B, C and D virus infection amongst patients with features of hepatitis in a referral hospital in Botswana: A cross-sectional study. S Afr J Infect Dis 2021;36:275. [PMID: 39372168 PMCID: PMC11451164 DOI: 10.4102/sajid.v36i1.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Accepted: 05/05/2021] [Indexed: 10/08/2024] Open

Mohareb AM, Menan Kouamé G, Gabassi A, Gabillard D, Moh R, Badje A, Emième A, Maylin S, Ménan H, Hyle EP, Delaugerre C, Danel C, Anglaret X, Lacombe K, Eholié SP, Boyd A. Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy. J Viral Hepat 2021;28:621-629. [PMID: 33382189 PMCID: PMC7946742 DOI: 10.1111/jvh.13461] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 12/07/2020] [Indexed: 12/12/2022]

Abstract

It is unknown how past and active hepatitis B virus (HBV) infection affect immunorecovery and mortality in people with HIV who initiate tenofovir-based antiretroviral therapy (ART). Using data collected between 2008 and 2015, we studied people with HIV in sub-Saharan Africa initiating immediate ART in the Temprano randomized control trial. We classified participants into HBV groups at ART initiation: hepatitis B surface antigen (HBsAg)-positive with HBV DNA ≥ 2,000 IU/ml; HBsAg-positive with HBV DNA < 2,000 IU/ml; isolated HBcAb-positive; resolved infection (HBsAb-positive/HBcAb-positive); and HBV non-immune/vaccinated (HBcAb-negative). We compared square-root CD4-cell count increases using mixed-effect, non-linear regression adjusted for age, sex, baseline CD4 cell count, and HIV RNA. We compared all-cause mortality using Bayesian parametric survival regression. Among 879 participants, 24 (2.7%) had HBsAg with high HBV DNA, 76 (8.6%) HBsAg with low HBV DNA, 325 (37.0%) isolated anti-HBcAb, 226 (25.7%) resolved HBV infection and 228 (25.9%) HBV non-immune/vaccinated. We found no significant difference in CD4 cell increases between HBV-infection groups after adjustment (p = 0.16). Participants with HBsAg and high HBV DNA had the highest incidence of all-cause mortality (1.9/100 person-years, 95% Credibile Interval [CrI] = 1.0-3.4). By comparison, incidence rates of mortality were reduced by 57% (95%CrI = -79%, -13%), 60% (95%CrI = -82%, -12%) and 66% (95%CrI = -84%, -23%) in those who had isolated anti-HBcAb-positive, resolved HBV infection and HBV non-immune/vaccinated, respectively. In conclusion, individuals with HIV and past HBV infection or isolated anti-HBcAb-positive serology, much like HBV non-immune/vaccinated, experience lower mortality than those with HBsAg and high HBV DNA. Additional HBV-related management would not be necessary for these individuals.

Collapse

Affiliation(s)

Amir M. Mohareb Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, USA.,Division of Infectious Diseases, Massachusetts General Hospital, Boston, USA.,Harvard Medical School, Boston, USA
Gérard Menan Kouamé Programme PAC-CI site ANRS de Côte d’Ivoire, Abidjan, Côte d’Ivoire.,INSERM UMR1219 IDLIC, Bordeaux, France
Audrey Gabassi
Delphine Gabillard INSERM UMR1219 IDLIC, Bordeaux, France.,University of Bordeaux, France
Raoul Moh Programme PAC-CI site ANRS de Côte d’Ivoire, Abidjan, Côte d’Ivoire.,Service des Maladies Infectieuses et Tropicale, CHU de Treichville, Abidjan, Côte d’Ivoire
Anani Badje Programme PAC-CI site ANRS de Côte d’Ivoire, Abidjan, Côte d’Ivoire.,Service des Maladies Infectieuses et Tropicale, CHU de Treichville, Abidjan, Côte d’Ivoire
Arlette Emième Service des Maladies Infectieuses et Tropicale, CHU de Treichville, Abidjan, Côte d’Ivoire
Sarah Maylin Laboratoire de Virologie, Hôpital Saint-Louis, AP-HP, Paris, France
Hervé Ménan Laboratoire CeDreS, CHU Treichville, Abidjan, Côte d’Ivoire
Emily P. Hyle Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, USA.,Division of Infectious Diseases, Massachusetts General Hospital, Boston, USA.,Harvard Medical School, Boston, USA.,Harvard Center for AIDS Research, Boston, USA
Constance Delaugerre Laboratoire de Virologie, Hôpital Saint-Louis, AP-HP, Paris, France.,INSERM U944, Institut de Recherche Saint-Louis, Paris, France
Christine Danel Programme PAC-CI site ANRS de Côte d’Ivoire, Abidjan, Côte d’Ivoire.,INSERM UMR1219 IDLIC, Bordeaux, France.,University of Bordeaux, France
Xavier Anglaret Programme PAC-CI site ANRS de Côte d’Ivoire, Abidjan, Côte d’Ivoire.,INSERM UMR1219 IDLIC, Bordeaux, France.,University of Bordeaux, France
Karine Lacombe INSERM, UMR_S1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France.,Service des maladies infectieuses et tropicales, Hôpital Saint-Antoine, AP-HP, Paris, France
Serge P. Eholié Programme PAC-CI site ANRS de Côte d’Ivoire, Abidjan, Côte d’Ivoire.,Service des Maladies Infectieuses et Tropicale, CHU de Treichville, Abidjan, Côte d’Ivoire
Anders Boyd INSERM, UMR_S1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France.,Corresponding author: Anders Boyd, MPH, PhD, Stichting HIV Monitoring, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands,

Collapse

MacLeod IJ, Rowley CF, Essex M. PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens. Commun Biol 2021;4:227. [PMID: 33603155 PMCID: PMC7892852 DOI: 10.1038/s42003-021-01751-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Accepted: 12/21/2020] [Indexed: 02/06/2023] Open

Malagnino V, Teti E, Compagno M, Coppola L, Salpini R, Svicher V, Basso M, Battagin G, Panese S, Rossi MC, Scaggiante R, Zago D, Iannetta M, Parisi SG, Andreoni M, Sarmati L. HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort. Microorganisms 2021;9:microorganisms9020396. [PMID: 33671934 PMCID: PMC7919011 DOI: 10.3390/microorganisms9020396] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 02/09/2021] [Accepted: 02/11/2021] [Indexed: 01/31/2023] Open

Affiliation(s)

Vincenzo Malagnino Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.) Dipartimento di Medicina dei Sistemi, Facoltà di Medicina, Università degli studi di Roma Tor Vergata, 00133 Rome, Italy Correspondence: ; Tel.: +390-620-902-790
Elisabetta Teti Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
Mirko Compagno Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
Luigi Coppola Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.)
Romina Salpini Dipartimento di Medicina Sperimentale, Università degli Studi di Roma Tor Vergata, 00133 Rome, Italy; (R.S.); (V.S.)
Valentina Svicher Dipartimento di Medicina Sperimentale, Università degli Studi di Roma Tor Vergata, 00133 Rome, Italy; (R.S.); (V.S.)
Monica Basso Dipartimento di Medicina Molecolare, Università degli Studi di Padova, 35128 Padova, Italy; (M.B.); (D.Z.); (S.G.P.)
Giuliana Battagin UOC Malattie Infettive, Ospedale di Vicenza, 36100 Vicenza, Italy;
Sandro Panese UOC Malattie Infettive Ospedale di Venezia, 30122 Venezia, Italy;
Maria Cristina Rossi UOC Malattie Infettive Ospedale di Treviso, 31100 Treviso, Italy;
Renzo Scaggiante UOC Malattei Infettive, Ospedale di Belluno, 32100 Belluno, Italy;
Daniela Zago Dipartimento di Medicina Molecolare, Università degli Studi di Padova, 35128 Padova, Italy; (M.B.); (D.Z.); (S.G.P.)
Marco Iannetta Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.) Dipartimento di Medicina dei Sistemi, Facoltà di Medicina, Università degli studi di Roma Tor Vergata, 00133 Rome, Italy
Saverio Giuseppe Parisi Dipartimento di Medicina Molecolare, Università degli Studi di Padova, 35128 Padova, Italy; (M.B.); (D.Z.); (S.G.P.)
Massimo Andreoni Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.) Dipartimento di Medicina dei Sistemi, Facoltà di Medicina, Università degli studi di Roma Tor Vergata, 00133 Rome, Italy
Loredana Sarmati Clinica di Malattie Infettive, Policlinico Tor Vergata di Roma, 00133 Rome, Italy; (E.T.); (M.C.); (L.C.); (M.I.); (M.A.); (L.S.) Dipartimento di Medicina dei Sistemi, Facoltà di Medicina, Università degli studi di Roma Tor Vergata, 00133 Rome, Italy

Collapse

Serikova EN, Semenov AV, Ostankova YV, Totolian AA. Method for detecting hepatitis B virus in blood plasma at low viral load using real-time PCR. Klin Lab Diagn 2021;66:59-64. [PMID: 33567175 DOI: 10.18821/0869-2084-2021-66-1-59-64] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]

Abstract

A method for detecting HBV DNA in peripheral blood at low viral load using real-time PCR was developed and its significance in identifying HBsAg-negative viral hepatitis B was evaluated. When developing the method, blood plasma samples and liver tissue biopsy material were used from 128 patients living in St. Petersburg, in various regions of the Russian Federation, as well as in the Central Asia countries. We also used blood plasma samples from 96 pregnant women and 37 hemodialysis center patients living in Northwestern Federal District, 199 foreign citizens undergoing medical examination to obtain work permits at the Directorate for Migration in the Northwestern Federal District, 397 conditionally healthy people living in the Socialist Republic of Vietnam. HBV was detected by nested PCR. Analytical sensitivity was tested using the stepwise dilution method. According to the method developed by us, at the first stage, the HBV DNA is amplified using at the first stage oligonucleotides flanking the genome region 2932-3182 ... 1-1846 nt., and at the second stage two oligonucleotides pairs to the genome virus regions (gene S and gene X) and corresponding oligonucleotide fluorescently labeled probes complementary to the amplified fragments regions carrying fluorophores at the 5'-end, and non-fluorescent quenchers at the 3'-end. The channel corresponding to the FAM fluorophore detects the HBV DNA S-region amplification product, and the channel corresponding to the ROX fluorophore detects the HBV DNA X-region amplification product. The method sensitivity for DNA extraction from plasma with a 100 μl volume was 10 IU/ml. Obtaining a threshold cycle Ct for only one FAM or ROX fluorophore may indicate the HBV DNA presence in a sample at a load of less than 10 IU / ml, HBV detection in this case is possible with a repeated PCR study of the corresponding sample with HBV DNA extraction from an increased plasma volume (200-1000 μl). The developed method makes it possible to identify various HBV genovariants, both characteristic and rare in the Russian Federation, circulating in other world regions. The method can be used to detect HBV in risk groups, in the population, as well as in screening blood donors in order to ensure the blood transfusions safety.

Collapse

Salyani A, Shah J, Adam R, Otieno G, Mbugua E, Shah R. Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults. PLoS One 2021;16:e0244947. [PMID: 33406137 PMCID: PMC7787452 DOI: 10.1371/journal.pone.0244947] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2020] [Accepted: 12/18/2020] [Indexed: 01/15/2023] Open

Salpini R, Malagnino V, Piermatteo L, Mulas T, Alkhatib M, Scutari R, Teti E, Cerva C, Yu La Rosa K, Brugneti M, Bertoli A, Rossi B, Holzmayer V, Gersch J, Kuhns M, Cloherty G, Ceccherini-Silberstein F, Perno CF, Iannetta M, Andreoni M, Sarmati L, Svicher V. Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. Microorganisms 2020;8:microorganisms8111819. [PMID: 33218205 PMCID: PMC7699270 DOI: 10.3390/microorganisms8111819] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 11/09/2020] [Accepted: 11/17/2020] [Indexed: 12/14/2022] Open

Affiliation(s)

Romina Salpini Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; (R.S.); (L.P.); mohammad-- (M.A.); (R.S.); (K.Y.L.R.); (M.B.); (A.B.); (F.C.-S.)
Vincenzo Malagnino Clinic of Infectious Diseases, Tor Vergata University Hospital, 00133 Rome, Italy; (V.M.); (T.M.); (E.T.); (C.C.); (B.R.); (M.I.); (M.A.); (L.S.)
Lorenzo Piermatteo Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; (R.S.); (L.P.); mohammad-- (M.A.); (R.S.); (K.Y.L.R.); (M.B.); (A.B.); (F.C.-S.)
Tiziana Mulas Clinic of Infectious Diseases, Tor Vergata University Hospital, 00133 Rome, Italy; (V.M.); (T.M.); (E.T.); (C.C.); (B.R.); (M.I.); (M.A.); (L.S.)
Mohammad Alkhatib Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; (R.S.); (L.P.); mohammad-- (M.A.); (R.S.); (K.Y.L.R.); (M.B.); (A.B.); (F.C.-S.)
Rossana Scutari Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; (R.S.); (L.P.); mohammad-- (M.A.); (R.S.); (K.Y.L.R.); (M.B.); (A.B.); (F.C.-S.)
Elisabetta Teti Clinic of Infectious Diseases, Tor Vergata University Hospital, 00133 Rome, Italy; (V.M.); (T.M.); (E.T.); (C.C.); (B.R.); (M.I.); (M.A.); (L.S.)
Carlotta Cerva Clinic of Infectious Diseases, Tor Vergata University Hospital, 00133 Rome, Italy; (V.M.); (T.M.); (E.T.); (C.C.); (B.R.); (M.I.); (M.A.); (L.S.)
Katia Yu La Rosa Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; (R.S.); (L.P.); mohammad-- (M.A.); (R.S.); (K.Y.L.R.); (M.B.); (A.B.); (F.C.-S.)
Marta Brugneti Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; (R.S.); (L.P.); mohammad-- (M.A.); (R.S.); (K.Y.L.R.); (M.B.); (A.B.); (F.C.-S.)
Ada Bertoli Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; (R.S.); (L.P.); mohammad-- (M.A.); (R.S.); (K.Y.L.R.); (M.B.); (A.B.); (F.C.-S.)
Benedetta Rossi Clinic of Infectious Diseases, Tor Vergata University Hospital, 00133 Rome, Italy; (V.M.); (T.M.); (E.T.); (C.C.); (B.R.); (M.I.); (M.A.); (L.S.)
Vera Holzmayer Abbott Molecular, Des Plaines, IL 60018-3315, USA; (V.H.); (J.G.); (M.K.); (G.C.)
Jeffrey Gersch Abbott Molecular, Des Plaines, IL 60018-3315, USA; (V.H.); (J.G.); (M.K.); (G.C.)
Mary Kuhns Abbott Molecular, Des Plaines, IL 60018-3315, USA; (V.H.); (J.G.); (M.K.); (G.C.)
Gavin Cloherty Abbott Molecular, Des Plaines, IL 60018-3315, USA; (V.H.); (J.G.); (M.K.); (G.C.)
Francesca Ceccherini-Silberstein Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; (R.S.); (L.P.); mohammad-- (M.A.); (R.S.); (K.Y.L.R.); (M.B.); (A.B.); (F.C.-S.)
Carlo-Federico Perno Microbiology and Immunology Diagnostics, Ospedale Pediatrico Bambino Gesù, 00165 Rome, Italy;
Marco Iannetta Clinic of Infectious Diseases, Tor Vergata University Hospital, 00133 Rome, Italy; (V.M.); (T.M.); (E.T.); (C.C.); (B.R.); (M.I.); (M.A.); (L.S.)
Massimo Andreoni Clinic of Infectious Diseases, Tor Vergata University Hospital, 00133 Rome, Italy; (V.M.); (T.M.); (E.T.); (C.C.); (B.R.); (M.I.); (M.A.); (L.S.)
Loredana Sarmati Clinic of Infectious Diseases, Tor Vergata University Hospital, 00133 Rome, Italy; (V.M.); (T.M.); (E.T.); (C.C.); (B.R.); (M.I.); (M.A.); (L.S.)
Valentina Svicher Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy; (R.S.); (L.P.); mohammad-- (M.A.); (R.S.); (K.Y.L.R.); (M.B.); (A.B.); (F.C.-S.) Correspondence:

Collapse

Malagnino V, Cerva C, Cingolani A, Ceccherini-Silberstein F, Vergori A, Cuomo G, Perno CF, Puoti M, d'Arminio Monforte A, Cozzi-Lepri A, Andreoni M, Sarmati L. HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. Open Forum Infect Dis 2020;8:ofaa566. [PMID: 33447635 PMCID: PMC7781466 DOI: 10.1093/ofid/ofaa566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Accepted: 11/11/2020] [Indexed: 11/13/2022] Open

Jepkemei KB, Ochwoto M, Swidinsky K, Day J, Gebrebrhan H, McKinnon LR, Andonov A, Oyugi J, Kimani J, Gachara G, Songok EM, Osiowy C. Characterization of occult hepatitis B in high-risk populations in Kenya. PLoS One 2020;15:e0233727. [PMID: 32463824 PMCID: PMC7255601 DOI: 10.1371/journal.pone.0233727] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Accepted: 05/11/2020] [Indexed: 12/18/2022] Open

Phinius BB, Anderson M, Bokete R, Mbangiwa T, Choga WT, Baruti K, Makhema J, Musonda R, Blackard JT, Essex M, Moyo S, Marlink R, Gaseitsiwe S. Incidence of hepatitis B virus infection among human immunodeficiency virus-infected treatment naïve adults in Botswana. Medicine (Baltimore) 2020;99:e19341. [PMID: 32118769 PMCID: PMC7478615 DOI: 10.1097/md.0000000000019341] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open

Abstract

Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection is highest in sub-Saharan Africa and results in accelerated clinical outcomes compared with HBV or HIV mono-infection. HBV clearance rates are higher in healthy adults; however, in sub-Saharan Africa, there are limited data on clearance of incident HBV in HIV-infected adults. Therefore, we sought to estimate HBV incidence and HBV surface antigen (HBsAg) clearance in HIV-infected adults in Botswana.This was a retrospective longitudinal study of 442 HIV-1C infected treatment naïve patients enrolled in a previous Botswana Harvard AIDS Institute Partnership study. Archived plasma samples from 435 HIV-infected treatment naïve participants were screened for HBsAg and HBV core antibody (anti-HBc). HBsAg was evaluated annually over a 4-year period, and HBV deoxyribonucleic acid (DNA) levels of HBsAg-positive chronic and incident patients were quantified.Baseline median CD4+ T-cell count was 458 cells/μL [Q1, Q3: 373, 593], and median HIV viral load was 4.15 copies/mL [Q1, Q3: 3.46, 4.64]. Twenty two HBV incident cases occurred, representing an incidence of 3.6/100 person-years [95% CI: 2.2-5.6]. All incident HBV cases with a follow-up sample available for screening (13/22) cleared HBsAg. Detectable HBV viral loads among chronic and incident cases ranged between 5.15 × 10 to 1.4 × 10 IU/L and 1.80 × 10 to 1.7 × 10 IU/mL, respectively.We report high HBV incidence associated with elevated HBV DNA levels despite high CD4+ T-cell counts in HIV-infected patients in Botswana. These incidence cases represent a potential source of HBV transmission in the population. Scaling-up of HIV treatment strategies utilizing antiretroviral therapy regimens with anti-HBV activity coupled with screening for HBV infections in households of the HBsAg-positive cases is recommended.

Collapse

Liégeois F, Boyer S, Eymard-Duvernay S, Carrieri P, Kouanfack C, Domyeum J, Maradan G, Ducos J, Mpoudi-Ngolé E, Spire B, Delaporte E, Kuaban C, Vidal L, Laurent C. Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM). BMC Infect Dis 2020;20:49. [PMID: 31941464 PMCID: PMC6964089 DOI: 10.1186/s12879-020-4784-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Accepted: 01/09/2020] [Indexed: 01/17/2023] Open

Abstract

Background

Hepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients followed up as part of Cameroon’s national antiretroviral programme.

Methods

A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in 19 hospitals in the Centre and Littoral regions in Cameroon. The proportions of patients tested for hepatitis B surface antigen (HBsAg) prior to the study were compared among all study hospitals using the Chi-square test. The association of individual and hospital-related characteristics with HBV testing and virologic suppression was assessed using multilevel logistic regression models.

Results

Of 1706 patients (women 74%, median age 42 years, median time on ART 3.9 years), 302 (17.7%) had been tested for HBsAg prior to the study. The proportion of HBV-tested patients ranged from 0.8 to 72.5% according to the individual hospital (p < 0.001). HBV testing was lower in women (adjusted odds ratio [aOR] 0.64, 95% confidence interval [CI] 0.46–0.89, p = 0.010) and higher in patients who initiated ART in 2010 or later (aOR 1.66, 95% CI 1.23–2.27, p < 0.001). Of 159 HBsAg-positive patients at the time of the study (9.3%), only 97 (61.0%) received Tenofovir + Lamivudine (or Emtricitabine). Of 157 coinfected patients, 114 (72.6%) had a HBV viral load < 10 IU/mL. HBV suppression was higher in patients with a HIV viral load < 300 copies/mL (aOR 3.46, 95% CI 1.48–8.09, p = 0.004) and lower in patients with increased ALT level (aOR 0.86 per 10 IU/mL increase, 95% CI 0.75–0.97, p = 0.019).

Conclusions

A substantial proportion of HIV/HBV coinfected patients were at higher risk of liver disease progression. Improving the management of HBV infection in the routine healthcare setting in Africa is urgently required in order to achieve the 2030 elimination targets. Micro-elimination of HBV infection in people living with HIV could be an easier and cost-effective component than more widely scaling up HBV policies.

Collapse

Sarmati L, Malagnino V. HBV Infection in HIV-Driven Immune Suppression. Viruses 2019;11:v11111077. [PMID: 31752284 PMCID: PMC6893694 DOI: 10.3390/v11111077] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Revised: 11/15/2019] [Accepted: 11/16/2019] [Indexed: 12/17/2022] Open

Molecular Characterization of Near Full-Length Genomes of Hepatitis B Virus Isolated from Predominantly HIV Infected Individuals in Botswana. Genes (Basel) 2018;9:genes9090453. [PMID: 30205537 PMCID: PMC6162474 DOI: 10.3390/genes9090453] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Revised: 08/27/2018] [Accepted: 09/03/2018] [Indexed: 12/13/2022] Open

Short article: Hepatitis delta in patients with resolved hepatitis B virus infection. Eur J Gastroenterol Hepatol 2018;30:1063-1065. [PMID: 29927770 DOI: 10.1097/meg.0000000000001187] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]

Anderson M, Choga WT, Moyo S, Bell TG, Mbangiwa T, Phinius BB, Bhebhe L, Sebunya TK, Makhema J, Marlink R, Kramvis A, Essex M, Musonda RM, Blackard JT, Gaseitsiwe S. In Silico Analysis of Hepatitis B Virus Occult Associated Mutations in Botswana Using a Novel Algorithm. Genes (Basel) 2018;9:genes9090420. [PMID: 30134551 PMCID: PMC6162659 DOI: 10.3390/genes9090420] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Accepted: 08/16/2018] [Indexed: 02/06/2023] Open

Affiliation(s)

Motswedi Anderson Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Faculty of Science, Department of Biological Sciences, University of Botswana, Gaborone, Botswana.
Wonderful T Choga Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Sikhulile Moyo Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Trevor Graham Bell Hepatitis Virus Diversity Research Unit (HVDRU), Faculty of Health Sciences, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg 2050, South Africa.
Tshepiso Mbangiwa Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Faculty of Allied Health Sciences, University of Botswana, Gaborone, Botswana.
Bonolo B Phinius Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Lynette Bhebhe Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Theresa K Sebunya Faculty of Science, Department of Biological Sciences, University of Botswana, Gaborone, Botswana.
Joseph Makhema Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Richard Marlink Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. Rutgers Global Health Institute, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ 08854, USA.
Anna Kramvis Hepatitis Virus Diversity Research Unit (HVDRU), Faculty of Health Sciences, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg 2050, South Africa.
Max Essex Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Rosemary M Musonda Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Jason T Blackard College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Simani Gaseitsiwe Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Collapse

Blackard JT, Sherman KE. Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV). Rev Med Virol 2018;28:e1984. [PMID: 29761585 PMCID: PMC6233878 DOI: 10.1002/rmv.1984] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Revised: 04/04/2018] [Accepted: 04/05/2018] [Indexed: 12/16/2022]

Mbangiwa T, Kasvosve I, Anderson M, Thami PK, Choga WT, Needleman A, Phinius BB, Moyo S, Leteane M, Leidner J, Blackard JT, Mayondi G, Kammerer B, Musonda RM, Essex M, Lockman S, Gaseitsiwe S. Chronic and Occult Hepatitis B Virus Infection in Pregnant Women in Botswana. Genes (Basel) 2018;9:genes9050259. [PMID: 29772814 PMCID: PMC5977199 DOI: 10.3390/genes9050259] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 05/11/2018] [Accepted: 05/11/2018] [Indexed: 12/20/2022] Open

Affiliation(s)

Tshepiso Mbangiwa Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana. Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Gaborone 0022, Botswana.
Ishmael Kasvosve Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Gaborone 0022, Botswana.
Motswedi Anderson Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana. Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone 0022, Botswana.
Prisca K Thami Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana. Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone 0022, Botswana.
Wonderful T Choga Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana.
Austen Needleman Harvard College, Cambridge, MA 02138, USA.
Bonolo B Phinius Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana.
Sikhulile Moyo Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Melvin Leteane Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone 0022, Botswana.
Jean Leidner Goodtables Data Consulting, Norman, OK 73019, USA.
Jason T Blackard University of Cincinnati College of Medicine, Cincinnati, OH 45627, USA.
Gloria Mayondi Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana.
Betsy Kammerer Department of Psychiatry, Boston Children's Hospital, Boston, MA 02115, USA. Brigham and Women's Hospital, Boston, MA 02115, USA.
Rosemary M Musonda Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana.
Max Essex Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Shahin Lockman Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA. Brigham and Women's Hospital, Boston, MA 02115, USA.
Simani Gaseitsiwe Botswana Harvard AIDS Institute Partnership, Gaborone BO320, Botswana. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Collapse

Bivigou-Mboumba B, Amougou-Atsama M, Zoa-Assoumou S, M’boyis Kamdem H, Nzengui-Nzengui GF, Ndojyi-Mbiguino A, Njouom R, François-Souquière S. Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence. PLoS One 2018;13:e0190592. [PMID: 29315352 PMCID: PMC5760027 DOI: 10.1371/journal.pone.0190592] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Accepted: 12/17/2017] [Indexed: 12/15/2022] Open

Abstract

In Gabon, a central African country, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are endemic. In a recent study, conducted in a semi-urban area (Franceville, Gabon), HBV infection was found to be more prevalent among HIV infected individuals. This study aims to investigate the prevalence and genetic diversity of hepatitis B virus infection among HIV infected individuals, predominantly under antiretroviral therapy, living in fully urbanized area: Libreville, capital of Gabon. Serological and molecular tests were performed to detect HBV infection among patients living with HIV/AIDS (PLHA). We used Monolisa HBsAg ULTRA, Anti-HBc Plus and Anti-HBs Plus EIA kits for serological analyses. HBV DNA viral load (HBV DNA VL) was determined by real time PCR and molecular characterization of HBV strains was performed by sequencing and phylogenetic analysis of partial HBV surface and core genes. At all, 70.2% of patients were under antiretroviral therapy. The prevalence of HBsAg was 8.8% (43/487). Detectable HBV DNA was found in 69.7% (30/43) of HBsAg positive patients and in 17.5% (24/137) HBsAg negative patients. HBV DNA VL was significantly higher among patient with CD4 cell counts less than 200 cells/mm³ than those with CD4 cell counts greater than 500 cells/mm³ (p = 0.008). We confirmed the presence of HBV sub-genotypes QS-A3 (40%), and A4 (20%) and HBV-E genotype (40%). The percentage of resistance to Lamivudine was high (40%) and varied according to the M204V/I motif. Occult hepatitis B infection (OBI) was found in patients with isolated HBcAb and among patients who had completed their HBsAg seroconversion. We detected HBV DNA for one patient without any HBV serological marker. This study provides a new landmark for the comprehension of HBV infection in PLHA in urban areas. OBI enhances HBV DNA prevalence and should be investigated in all HBsAg negative individuals.

Collapse